Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 71 to 80 of 480 total matches.

Fiasp - Another Insulin Aspart Formulation for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018  (Issue 1537)
Fiasp – Another Insulin Aspart Formulation for Diabetes Table 1. Rapid-Acting Insulins Some ...
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog).
Med Lett Drugs Ther. 2018 Jan 1;60(1537):6-7 | Show Introduction Hide Introduction

Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
in young adulthood.1 No effective treatments have been available. The Argus II Retinal Prosthesis System ...
The FDA has approved voretigene neparvovec-rzyl intraocular suspension (Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells. It is the first gene replacement therapy approved in the US that targets a disease caused by mutations in a specific gene and the first pharmacologic treatment to be approved for this disorder.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-5 | Show Introduction Hide Introduction

Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
muscular atrophy (SMA) and bi-allelic mutations in the survival motor neuron 1 (SMN1) gene ...
The FDA has approved onasemnogene abeparvovec-xioi (Zolgensma – Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children <2 years old who have spinal muscular atrophy (SMA) and bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. It is the first gene therapy and the second drug to be approved in the US for SMA; nusinersen (Spinraza) was approved in 2016.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):113-4 | Show Introduction Hide Introduction

An EUA for Casirivimab and Imdevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
1. High-Risk Conditions for COVID-19 Outpatients1 ▶ Age ≥65 years ▶ BMI ≥25 kg/m2 (or, in patients ...
The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV) to be administered together by IV infusion or SC injection for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):201-2 | Show Introduction Hide Introduction

Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021  (Issue 1622)
/Rx Usual Dosage Comments Class Comments Cost1 H1-Antihistamines Azelastine 0.1%– generic Azelastine 0 ...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e66-71 | Show Introduction Hide Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
, and avoidance of eye rubbing and contact lens wearing during symptomatic periods.1 Many patients with allergic ...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 | Show Introduction Hide Introduction

Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
clinical trials, opicapone significantly reduced “off” time by about 1 hour, compared to placebo. In one ...
The FDA has approved opicapone (Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience "off" episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier. Opicapone has been available in Europe since 2016.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):3-5 | Show Introduction Hide Introduction

Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
of multidrugresistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure ...
The FDA has approved ibalizumab-uiyk (Trogarzo – Theratechnologies/TaiMed), a CD4-directed monoclonal antibody, for IV treatment of multidrug-resistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure on their current regimen. Ibalizumab-uiyk is the first biologic drug to be approved by the FDA for treatment of HIV-1 infection.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):68-9 | Show Introduction Hide Introduction

In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
for use in patients ≥4 years old.1 Children ...
The FDA has approved a new formulation of glucagon (Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products (Glucagon Emergency Kit, and others), Gvoke does not require...
Med Lett Drugs Ther. 2019 Nov 18;61(1585):186 | Show Introduction Hide Introduction

In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
instructions for starting treatment are complex. 1. Empagliflozin (Jardiance) for diabetes. Med Lett Drugs ...
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and extended-release metformin, for oral treatment of type 2 diabetes in adults. Empagliflozin and linagliptin have been available in a fixed-dose combination as Glyxambi since 2015, and both have been available in 2-drug combinations with extended-release metformin for years (see Table 1).
Med Lett Drugs Ther. 2020 Jun 1;62(1599):88 | Show Introduction Hide Introduction